Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins […]

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland […]

TriVascular (Santa Rosa, CA) a commercial-stage medical device company focused on endovascular repair devices for the treatment of abdominal aortic aneurysms, closed a $60M Series C financing. Participants include Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 […]

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust. Note: 2009 Year-in-Review Trend Analysis […]

TriVascular (Santa Rosa, CA) a clinical-stage medical device company focused on transluminally placed endovascular stent grafts for abdominal and thoracic aortic disease, closed a $30M Series B financing. Participants include New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...